Health AI Central
Share:
Peer-Reviewed Publication
J Clin Sleep Med2026;22(1)July 1, 2026Letter

Guideline clarification: dropout in FDA-cleared dCBT-I is comparable to pharmacotherapy and therapist-delivered CBT-I.

Alasdair L Henry1, Jenna R Carl2, Jason Ong3, Frances Thorndike3, Heidi Riney3, Nathaniel F Watson4, Colin A Espie2,5
1Big Health Inc., San Francisco, CA, USA. alasdair.henry@bighealth.com.
2Big Health Inc., San Francisco, CA, USA.
3Nox Health Inc., Alpharetta, GA, USA.
4Department of Neurology, University of Washington School of Medicine, Seattle, WA, USA.
5Sleep and Circadian Neuroscience Institute, Nuffield, Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
PubMed PMC DOI PDF

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.